Find Academic Supervisors

Daniel K. NomuraView profile

Professor

• Chemical Biology
• Molecular Therapeutics
• Targeted Protein Degradation
• +6 more

Professor Daniel K. Nomura is a faculty member in the Department of Chemistry at the University of California, Berkeley, with dual appointments in the Molecular Therapeutics Initiative and the Innovative Genomics Institute. His research focuses on reimagining druggability through chemoproteomic platforms to develop transformative medicines targeting undruggable proteins. He leads the Nomura Research Group, which explores three major research directions: chemoproteomics-enabled covalent ligand discovery, expanding targeted protein degradation technologies, and discovering new induced proximity-based therapeutic modalities. His work addresses challenges in drug discovery by identifying novel ligandable hotspots and developing covalent ligands for undruggable targets. Key projects include advancing molecular glue degraders, expanding E3 ligase recruitment strategies, and engineering protein localization through covalent interactions. The lab collaborates with industry partners such as Novartis and has spun out Vicinitas Therapeutics to commercialize protein stabilization therapies. Professor Nomura’s team includes graduate students, postdoctoral researchers, and staff scientists specializing in chemical biology, molecular therapeutics, and proteomics. His group actively publishes in top-tier journals like Journal of the American Chemical Society , Nature Chemical Biology , and Cell Chemical Biology , with a focus on translating fundamental research into clinical applications. Current funding and partnerships include the Novartis-Berkeley Translational Chemical Biology Institute and grants from institutions like The Mark Foundation for Cancer Research. The lab emphasizes training the next generation of chemical biologists through interdisciplinary projects spanning chemistry, biology, and medicine.

• Medical Imaging
• Radiology
• Prostate Cancer
• +7 more

Boris Bloch is an Adjunct Professor at the University of Massachusetts Chan Medical School's T.H. Chan School of Medicine , with appointments in the Radiology department and Urology department. His work focuses on Medical Imaging , particularly Prostate Cancer and Breast Cancer diagnostics using Magnetic Resonance Imaging (MRI) and Diagnostic Imaging techniques. Education: MD in Medicine and Psychology from University of Vienna, Austria Internship at Medical University Vienna, General Hospital Vienna, Austria Residency in Radiology at Harvard Medical School, Beth Israel Deaconess Medical Center, Boston Fellowships in MRI and Breast Imaging His research bridges Medical Informatics and Molecular Biology , with innovations in Radiomics , Image Registration Algorithms , and Biopsy Marker Technology . Bloch has contributed to Radio-Genomics approaches for predicting cancer risk scores and developed 3D-Printed Phantoms for radiation therapy. His work has been cited extensively, with 2019 studies on Prostate Tumor Detection and HER2-Positive Breast Cancer responses to therapy.

• Prostate Cancer
• Renal Cell Carcinoma
• Urologic Oncology
• +7 more

Rana McKay is a Clinical Professor in the School of Medicine at the University of California, San Diego (UCSD), specializing in oncology with a focus on genitourinary cancers. Her research spans prostate cancer, renal cell carcinoma, and urologic oncology, with significant contributions to clinical trials, biomarker development, and precision medicine approaches. Dr. McKay's research interests include prostate cancer therapeutics, particularly in metastatic castration-resistant prostate cancer (mCRPC), where she has led numerous clinical trials investigating novel treatments including androgen receptor targeting agents, PARP inhibitors, and immunotherapies. Her work extends to renal cell carcinoma, where she examines treatment sequencing, biomarker identification, and novel therapeutic combinations. She has made significant contributions to understanding health disparities in cancer outcomes, particularly among minority populations and cancer survivors. Analysis of Dr. McKay's publications reveals a strong focus on translational research with direct clinical applications. Her work spans multiple phases of clinical development, from early biomarker discovery to phase III clinical trials. A notable trend is her investigation of genomic alterations in prostate cancer, particularly related to DNA repair pathways and their implications for targeted therapy. She also has significant contributions in the area of health disparities, examining how factors like race, ethnicity, and socioeconomic status impact cancer outcomes. Dr. McKay has been actively involved in numerous multicenter clinical trials and consortia, collaborating with major cancer research groups internationally. Her extensive publication record demonstrates leadership in designing and implementing clinical research protocols that address critical gaps in genitourinary oncology.

• Radiation Oncology
• Immunotherapy
• Cancer Immunology
• +6 more

Dr. Andrew Sharabi is a physician scientist and board-certified radiation oncologist at UC San Diego Moores Cancer Center. He holds the position of Clinical Professor in the Department of Radiation Medicine and Applied Science within the School of Health Sciences at the University of California San Diego. Dr. Sharabi serves as Director of the Center for Precision Radiation Medicine and Radiation Medicine Core Facility at Moores Cancer Center and is Chair of the American Society of Therapeutic Radiology and Oncology (ASTRO) Education Committee - Immunotherapy Track. Dr. Sharabi's educational background includes: B.S. in Bioengineering from University of California at San Diego (2001) Ph.D. in Immunology from Baylor College of Medicine (2009) M.D. from Baylor College of Medicine (2010) Residency in Radiation Oncology at Johns Hopkins Hospital (2015) Dr. Sharabi is a recognized expert on the effects of radiation on the immune system and the ability of radiation therapy to synergize with checkpoint blockade immunotherapy. His research focuses on developing novel immunotherapies and strategies to combine radiation with immunotherapy, particularly for head and neck cancers and prostate (genitourinary) cancers. He treats patients with advanced radiotherapy techniques including intensity modulated radiotherapy (IMRT), image-guided radiotherapy (IGRT), 4-D computed tomography, and Stereotactic Body Radiation Therapy (SBRT). His work has significant implications for improving cancer treatment outcomes through the strategic combination of radiation and immunotherapy. Analysis of Dr. Sharabi's recent publications reveals a strong focus on the intersection of radiation oncology and immunotherapy. His research spans multiple cancer types, with particular emphasis on head and neck squamous cell carcinoma (HNSCC) and genitourinary cancers. Key themes include the sequencing of radiation and immunotherapy, mechanisms of immune activation following radiation, biomarker development for treatment personalization, and strategies to overcome resistance to combined modality therapy. His work frequently appears in high-impact journals including Nature Communications and Lancet Oncology, demonstrating the significance of his contributions to the field. Dr. Sharabi has received numerous prestigious awards and honors throughout his career: Association of Residents in Radiation Oncology (ARRO) Educator of the Year Award (2020) Academy of Clinician Scholars Whitehill Award for Excellence in Teaching (2019) American Cancer Society (ACS) Cancer Care Champion - Radiation Oncologist of the Year (2019) UCSD ACTRI KL2 Translational Science Award (2017) Multiple awards from the American Society for Radiation Oncology (ASTRO) including the Roentgen Resident/Fellow Research Award (2015) As Principal Investigator, Dr. Sharabi leads multiple NIH-funded research projects including 'Investigating Mechanisms of Hyperprogression on Anti-PD-1 Immunotherapy' (NIH R21CA256360) and 'Role of B-cell mediated anti-tumor antibodies in responses to radiation and immunotherapy in HNSCC' (NIH/NIDCR R01DE028563). His research program combines basic science investigations with clinical trials, bridging the gap between laboratory discoveries and patient care. While specific information about his advisees is not provided in the available materials, his leadership roles suggest he mentors numerous students, residents, and fellows in radiation oncology and cancer research. Dr. Sharabi directs the Center for Precision Radiation Medicine and Radiation Medicine Core Facility at Moores Cancer Center, where his NIH-funded laboratory focuses on developing novel immunotherapies and strategies to combine radiation with immunotherapy. His research team likely includes postdoctoral fellows, graduate students, research technicians, and clinical collaborators working across disciplines to advance cancer treatment through innovative combinations of radiation and immunotherapy.

• Urology
• Prostate Cancer
• Medical Imaging
• +3 more

Masatomo Kaneko is an Assistant Professor of Research Urology at the University of Southern California. His primary affiliation is with the Department of Urology, focusing on innovative diagnostic and therapeutic approaches in prostate cancer and urological conditions. His research integrates artificial intelligence, medical imaging, and minimally invasive surgical techniques to improve patient outcomes and streamline diagnostic pathways. Dr. Kaneko’s work emphasizes prostate cancer management, including focal therapy, image-guided biopsies (MRI/TRUS fusion), and the application of AI for automated diagnosis and segmentation. He explores sustainable healthcare practices, such as the 'One-Stop' diagnostic pathway to reduce environmental impact. His studies often involve large, diverse cohorts and comparative analyses of surgical techniques and biopsy methodologies. He has contributed to evaluating the efficacy of transperineal vs. transrectal biopsy approaches, microwave focal therapy, and nomograms for predicting prostate cancer significance. His work also addresses broader academic equity issues, such as gender disparities in editorial board representation within urology journals. Dr. Kaneko collaborates on interdisciplinary projects, including virtual reality for surgical planning and AI-driven pathology analysis. His research bridges clinical practice and technological innovation, aiming to enhance diagnostic accuracy, patient experience, and treatment personalization.

• Mass Spectrometry
• Proteomics
• Clinical Prognostic Markers
• +3 more

Jonathan Katz, PhD, is an Assistant Professor of Research Medicine at the University of Southern California (USC). His work focuses on advancing mass spectrometry and proteomics technologies to discover clinical prognostic markers. Education: B.S. in Microbiology & Molecular Genetics B.S. in Cognitive Science PhD in Biochemistry and Molecular Biology from UCLA Dr. Katz's research spans proteomic profiling for drug response biomarkers, tumor microenvironment modeling using organ-on-chip systems, and cloud-based mass spectrometry data analysis. His publications demonstrate expertise in cancer biology, protein signaling, and computational biology tools. Recent work emphasizes colorectal cancer metastasis mechanisms, synthetic peptide development for cancer therapy, and virtualization of laboratory instrumentation systems. He contributes to methodological advancements in proteomics and bioinformatics. Contact: katzj@usc.edu

• Ultrasound Imaging
• Microvascular Imaging
• Medical Imaging
• +7 more

Dr. Vassilis Sboros is an Associate Professor at Heriot-Watt University's School of Engineering & Physical Sciences and an Honorary Fellow at the University of Edinburgh. His research bridges physics, engineering, and life sciences, focusing on ultrasound imaging, microvascular flow dynamics, and microbubble mechanics. He leads projects on super-resolution ultrasound imaging for cancer detection and cardiovascular applications. **Education and Career**: He has held roles including BHF Intermediate Basic Science Research Fellow (2007–2011) and Research Fellowships at the University of Edinburgh (2003–2012). His work contributes to UN Sustainable Development Goals in health and innovation. **Research Interests**: Microvascular imaging biomarkers, ultrasound contrast agents, and in vivo preclinical imaging. His lab develops algorithms for super-resolution imaging and vascular-specific ultrasound techniques. **Awards**: BHF Intermediate Basic Science Research Fellowship (2007–2011). His work has produced over 100 publications, emphasizing medical imaging advancements and translational research.

Emma BoldersonView profile

Adjunct Associate Professor

• Cancer Genomics
• DNA Damage Response
• DNA Repair Pathways
• +4 more

Adjunct Associate Professor Emma Bolderson is affiliated with Queensland University of Technology (QUT), holding a position in the School of Biomedical Sciences within the Faculty of Health . She holds a PhD from the University of Sheffield. Her research focuses on genomic stability, DNA repair mechanisms, and cancer therapeutics, with a particular emphasis on proteins involved in DNA damage response pathways such as hSSB1, Banf1, and PARP1. Education: PhD (University of Sheffield) Her research interests span cancer genomics, DNA repair pathways, and the development of targeted therapies for cancers such as lung, breast, and colorectal cancers. Key areas include studying proteins like hSSB1, COMMD4, and Aldolase A, which play roles in DNA damage repair and tumor progression. She also explores the therapeutic potential of inhibiting DNA repair pathways to enhance chemotherapy efficacy. Recent work highlights her contributions to understanding how proteins like Banf1 regulate PARP1 activity under oxidative stress, and how Aldolase A facilitates DNA repair processes. She has also explored nuclear membrane proteins' roles in tumorigenesis and their potential as therapeutic targets. Her publications demonstrate expertise in molecular biology, biochemistry, and translational oncology, with a focus on translating basic research findings into clinical applications. Emma collaborates with teams investigating drug targets, such as Aurora B kinase and CDCA3, to improve cancer treatment outcomes. Labs/Teams: Involved in the Centre for Genomics and Personalised Health and collaborates with interdisciplinary groups at QUT to advance personalized cancer therapies.

Elizabeth WilliamsView profile

Adjunct Associate Professor

• Oncology
• Cancer Biology
• Biochemistry
• +4 more

Adjunct Associate Professor Elizabeth Williams is affiliated with the School of Biomedical Sciences within the Faculty of Health at Queensland University of Technology (QUT). She holds a PhD and Bachelor of Science (Honours) from The University of Melbourne. Her research focuses on oncology and carcinogenesis, with particular emphasis on prostate and bladder cancers, biochemistry, and cell biology. Her work explores tumor microenvironment dynamics, patient-derived models, and immunotherapy approaches. Her research interests include the molecular mechanisms of cancer progression, targeted therapies for treatment-resistant cancers, and the application of precision medicine tools such as patient-derived organoids and xenograft models. She has contributed to studies on circulating tumor cells, androgen receptor signaling pathways, and the role of bacterial pathogens in cancer development. Recent publications highlight her work on Neisseria species' carcinogenic potential, challenges in prostate cancer patient-derived models, and immunophenotypic analysis of bladder cancer. Her research bridges basic science and clinical applications, aiming to improve therapeutic strategies for metastatic and treatment-resistant cancers. Elizabeth Williams collaborates on projects involving molecular profiling, tumor microenvironment deconvolution, and computational modeling of cancer growth dynamics. Her contributions to the field are reflected in her extensive publication record, with a focus on translational research impacting clinical oncology.

Bo LennernäsView profile

Professor

• Medical Science
• Oncology
• Brachytherapy
• +5 more

Bo Lennernäs (1963–2021) was a Professor of Medical Science at Örebro University. He held previous academic positions, including Adjunct Senior Lecturer at the University of Gothenburg (2005) and Docent in Medical Science at the University of Gothenburg (2001). His primary affiliation was with Örebro University, where he focused on prostate cancer therapy and radiotherapy innovations. Born in Bollnäs, Sweden, he earned his PhD in Medical Science at Uppsala University in 1996 with a thesis on radiotherapy of prostatic cancer. Education MD and specialist training in Oncology at Uppsala University PhD (1996): Radiotherapy of prostatic cancer – with reference to positioning and three-dimensional dose-planning His research emphasized improving radiotherapy techniques, such as four-dimensional radiotherapy using electromagnetic positioning systems, and reducing side effects of hormone therapy for prostate cancer patients. He co-developed the pharmaceutical Abstral (for breakthrough pain) with his brother, Professor Hans Lennernäs, and explored applications of medical robotics in healthcare. Key projects include a Nyckelfonden-funded study on electromagnetic tumor positioning during radiotherapy and a Finland-based trial of localized hormone therapy to minimize systemic side effects. Lennernäs held patents for medical devices and was a pioneer in integrating technology with oncology. His legacy includes advancing brachytherapy, hormone therapy optimization, and interdisciplinary collaborations in healthcare innovation.

Sugata BanerjiView profile

Associate Professor

• Computer Vision
• Scene Understanding
• Machine Learning
• +3 more

Sugata Banerji is an Associate Professor of Computer Science at Lake Forest College and Director of the Applied Data Center. His research focuses on computer vision, scene understanding, and machine learning, with applications in medical imaging and image retrieval. He holds a PhD in Computer Science from New Jersey Institute of Technology (2013) and a Postdoctoral fellowship in Computer Vision at George Mason University (2013–present). His educational background also includes a BE in Information Technology from West Bengal University of Technology. Research Interests include image processing, pattern recognition, and novel descriptors for object and scene classification. His work spans deep learning for medical diagnostics, efficient feature extraction methods like EFM-HOG, and geo-localization of buildings using computer vision. He has received the Department of Computer Science Travel Award (2012) and served as a Teaching Assistant (2008–2013). Key contributions include advancements in HOG descriptor variants (e.g., HaarHOG), color-based feature integration, and solar energy growth modeling. He teaches courses such as Roadmap to Computing with Python and Introduction to Computer Science, emphasizing practical programming and graphics problem-solving.

• Urology
• Prostate Cancer Diagnosis
• Bladder Cancer Treatment
• +3 more

Ralph J. DeVito, MD, is an Assistant Professor of Urology at Yale School of Medicine with over 40 years of clinical experience. He specializes in endourology, prostate/bladder cancer diagnostics, renal stone disease, and benign prostatic hypertrophy (BPH). His clinical practice emphasizes minimally invasive approaches such as Artemis fusion biopsies using 3D MRI and cystoscopy. Education: BA from Hamilton College (1970), MD from Albany Medical College (1974), General Surgery residency at Hospital of St. Raphael (1974-79), and Urology residency at Yale (1979-82). Board-certified in Urology since 1984. Research interests focus on advancing prostate cancer imaging and non-invasive treatments for localized tumors. Notable contributions include work on focal therapy and MRI-guided biopsy techniques. Active in departmental leadership roles, serving on multiple committees including the Executive Committee of the Department of Urology (2013-2021). Awards: Recognized as Connecticut Best Doctors (2018-2020). Involved in institutional initiatives like the Yale Urology clinical expansion and departmental "Shark Tank" innovation competitions.

• Bladder Cancer
• Prostate Cancer
• Kidney Cancer
• +7 more

Dr. Jonathan Kam is a Senior Clinical Lecturer in Urology at the University of Sydney's Sydney Medical School, affiliated with the Nepean Clinical School and the Faculty of Medicine and Health (FMH). He holds dual clinical and academic roles, specializing in urological cancers and innovative surgical techniques. His research focuses on bladder, prostate, kidney, and testicular cancers, as well as radiation-induced urological damage and reconstructive surgery. Dr. Kam completed his BMed and BSci(Med)Hons at the University of New South Wales (UNSW), graduating with distinction and earning prestigious awards including the Scientia Scholarship and UNSW Medicine Foundation Medal. He furthered his expertise through a Royal College of Surgeons Senior Clinical Fellowship at Guy’s Hospital, London, focusing on complex urological cancers. His academic roles have included positions at the University of Newcastle and UNSW, alongside research fellowships at the University of Sydney. His research has yielded over 50 peer-reviewed articles, book chapters, and case reports, with publications in journals like British Journal of Urology International and International Journal of Urology . He has presented at over 100 conferences globally. Key awards include the Board of Urology Frank Gardiner Award (2018), Chris Farrell Prize (2019), and George Schnitzler Award (2021). Dr. Kam’s clinical affiliations include the Nepean Urology Centre and Sydney Urology Associates, where he integrates cutting-edge treatments into patient care. His work emphasizes advancing diagnostic techniques (e.g., PSMA PET/CT, MRI accuracy) and improving outcomes for urological cancers through surgery and technology. Notable contributions include studies on ChatGPT’s role in prostate cancer education, comparative CT imaging techniques, and innovations in lithotripsy. He advocates for minimizing radiation exposure and optimizing surgical tools, as seen in his work on single-use ureteroscopes and laser settings.

• Urology
• Prostate Cancer
• Telemedicine
• +7 more

Professor Mohamed Khadra is a Professor of Surgery at the University of Sydney's Sydney Medical School. He holds leadership roles as Clinical Director of Surgery and Anaesthetics, and Director of Strategy and Innovation at Nepean Blue Mountains Local Health District. He also chairs the Nepean Telehealth Technology Centre and is Senior Faculty at the Cognitive Institute Pty Ltd. His research focuses on urology, prostate cancer, telemedicine, and surgical leadership. Key contributions include translational research, male incontinence management, and surgical education. He has authored books such as *Making the Cut: A Surgeon's Stories Of Life On The Edge* and *Honour, Duty and Courage*. Prof. Khadra's awards include the Officer of the Order of Australia (2017) and the Sydney University Alumni Medal (2015). He has led major initiatives like the Nepean Telehealth Technology Centre and contributed to national healthcare committees. Grants include the 2013 ATVRE grant for virtual rehabilitation engineering. His work spans surgical training, telehealth innovation, and prostate cancer imaging advancements.

• Cardiovascular Physiology
• Vascular Biology
• Autonomic Neuroscience
• +5 more

Professor Craig Daly holds the position of Professor of Physiology in the School of Cardiovascular & Metabolic Health at the University of Glasgow. He has been affiliated with the university since 1980, progressing through roles such as research technician, research fellow, and lecturer before achieving his current academic rank. His research focuses on vascular physiology, autonomic nervous system regulation of blood vessels, and the integration of advanced imaging and VR technologies into medical education and research. Education: Completed MSc and PhD in Medicine through the University of Glasgow's Faculty of Medicine. Awarded a Senior Fellowship of the Higher Education Academy in 2017. Research Interests: Specializes in vascular structure/function, adrenergic receptor distribution, and the application of confocal microscopy, 3D imaging, and virtual reality for biomedical visualization and education. Recent work includes developing mixed-reality tools for medical training and VR-based anatomical models. Publications: Over 150 peer-reviewed articles since 1985, emphasizing vascular biology, pharmacology, and innovative teaching methodologies. Recent trends include VR/AR applications in education, molecular dynamics of receptors, and biomedical visualization techniques. Awards: Recognized for contributions to education with the 2017 Higher Education Academy Senior Fellowship. Labs/Teams: Active in research groups such as Cellular Signalling & Mechanisms and Vascular Structure & Function. Collaborates on projects involving medical animation, drug-receptor interactions, and technology-driven learning solutions.